Explore

Trendline Trendline
Adagio Medical to Present at BofA Securities 2026 Healthcare Conference

Adagio Medical to Present at BofA Securities 2026 Healthcare Conference

Adagio Medical to Present at BofA Securities 2026 Healthcare Conference
Trendline Trendline
NutriBand Reports $2.04M Revenue and $8.23M Net Loss for Fiscal Year 2026

NutriBand Reports $2.04M Revenue and $8.23M Net Loss for Fiscal Year 2026

NutriBand Reports $2.04M Revenue and $8.23M Net Loss for Fiscal Year 2026
Trendline Trendline
Adagio Medical to Present at BofA Securities 2026 Health Care Conference

Adagio Medical to Present at BofA Securities 2026 Health Care Conference

Adagio Medical to Present at BofA Securities 2026 Health Care Conference
Trendline Trendline
Adagio Medical to Present at BofA Securities 2026 Healthcare Conference Highlighting Cardiac Arrhythmia Innovations

Adagio Medical to Present at BofA Securities 2026 Healthcare Conference Highlighting Cardiac Arrhythmia Innovations

Adagio Medical to Present at BofA Securities 2026 Healthcare Conference Highlighting Cardiac Arrhythmia Innovations
Rapid Read Rapid Read
Affinia Therapeutics Advances Gene Therapy for Heart Condition at ASGCT Meeting

Affinia Therapeutics Advances Gene Therapy for Heart Condition at ASGCT Meeting

Affinia Therapeutics, a clinical-stage biotech company, is set to present new preclinical data on its lead program, AFTX-201, at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting. AFTX-201 is an investigational genetic medicine designed to treat BAG3-associated dilated cardiomyopathy (DCM), a serious inherited heart condition. The therapy uses Affinia's proprietary capsid technology to deliver a BAG3 transgene efficiently at lower doses than conventional methods. The U.S. FDA has granted Fast Track designation for AFTX-201, and the European Medicines Agency has given it Orphan Drug designation. The UPBEAT clinical trial is currently investigating the safety and efficacy of AFTX-201.
Trendline Trendline
Eli Lilly's Foundayo Weight Loss Pill Sees Strong Initial Demand with Over 20,000 Users

Eli Lilly's Foundayo Weight Loss Pill Sees Strong Initial Demand with Over 20,000 Users

Eli Lilly's Foundayo Weight Loss Pill Sees Strong Initial Demand with Over 20,000 Users
Rapid Read Rapid Read
FDA Advisory Committee to Review AstraZeneca's Cancer Drug Applications Amid Concerns

FDA Advisory Committee to Review AstraZeneca's Cancer Drug Applications Amid Concerns

The FDA is set to hold its first drug-related advisory committee meeting in nine months to evaluate AstraZeneca's applications for two cancer drugs. The meeting will focus on the oral SERD drug camizestrant for HR-positive, HER2-negative breast cancer and the AKT inhibitor Truqap for metastatic hormone-sensitive prostate cancer. The FDA has raised questions about the clinical benefits and trial designs of these drugs, particularly regarding the validity of results and the timing of treatment interventions. The advisory panel will assess whether AstraZeneca has provided sufficient evidence to support the clinical benefits of these drugs.
Trendline Trendline
enVVeno Medical Secures FDA IDE Approval for Pivotal Study on Non-Surgical Venous Valve

enVVeno Medical Secures FDA IDE Approval for Pivotal Study on Non-Surgical Venous Valve

enVVeno Medical Secures FDA IDE Approval for Pivotal Study on Non-Surgical Venous Valve
Trendline Trendline
NeuroPace's RNS System Shows Significant Seizure Reduction in Epilepsy Patients

NeuroPace's RNS System Shows Significant Seizure Reduction in Epilepsy Patients

NeuroPace's RNS System Shows Significant Seizure Reduction in Epilepsy Patients
Trendline Trendline
Stealth BioTherapeutics Advances Bevemipretide Eye Drops for Dry AMD Treatment

Stealth BioTherapeutics Advances Bevemipretide Eye Drops for Dry AMD Treatment

Stealth BioTherapeutics Advances Bevemipretide Eye Drops for Dry AMD Treatment
Trendline Trendline
Intellia Therapeutics Announces Positive Phase 3 Results for Gene Editing Treatment in Hereditary Angioedema

Intellia Therapeutics Announces Positive Phase 3 Results for Gene Editing Treatment in Hereditary Angioedema

Intellia Therapeutics Announces Positive Phase 3 Results for Gene Editing Treatment in Hereditary Angioedema
Rapid Read Rapid Read
Intellia Therapeutics' Crispr-Based Treatment Achieves Success in Pivotal Trial

Intellia Therapeutics' Crispr-Based Treatment Achieves Success in Pivotal Trial

Intellia Therapeutics has announced that its Crispr-based treatment for hereditary angioedema has met its goals in a late-stage trial. The treatment, which edits DNA in vivo to turn off a gene causing overproduction of a peptide, reduced swelling attacks by 87% compared to a placebo. This marks a significant milestone in gene editing, as it is the first Phase 3 data for in vivo Crispr treatment. The company plans to seek FDA approval and aims to launch the treatment in the U.S. next year.